Journal of thrombosis and haemostasis : JTH · 2025
Population pharmacokinetics of edoxaban in geriatric patients with atrial fibrillation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Edwina Angela Elma, Van der Linden Lorenz, Debruyne Louise, Foerster Kathrin, Burhenne Jürgen, Verhamme Peter, Vanassche Thomas, Spriet Isabel, Dreesen Erwin, Tournoy Jos
Аннотация
BACKGROUND: Atrial fibrillation affects nearly half of geriatric inpatients, with edoxaban frequently used for stroke prevention. However, geriatric patients are underrepresented in drug trials with edoxaban. The limited data and high pharmacokinetic (PK) variability result in using this high-risk medication without a full understanding of its exposure in this population.
OBJECTIVES: To characterize the dose-exposure relationship and predict the sufficiency of current fixed-dose guideline for geriatric patients.
METHODS: We conducted a single-center prospective PK study in geriatric inpatients. We built a population PK model and used it to simulate various dosing strategies (n = 1000 simulations).
RESULTS: Seventeen frail geriatric patients (median age, 87 years; IQR, 83-90) receiving routine edoxaban contributed a total of 85 steady-state PK samples. A 2-compartment population PK model best described the edoxaban and M4 metabolite concentrations, with proton pump inhibitors (PPIs) reducing relative bioavailability by 24%. Key parameters included an absorption rate constant of 0.104 per hour, clearance of 9.02 L/h, and central and peripheral volumes of 47.4 L and 42.7 L, respectively. Edoxaban concentrations correlated with factor Xa inhibitor concentrations (ρ = .966). Nearly half of the patients had minimum concentrations > 43 ng/mL, with no difference between PPI and non-PPI groups. Simulations showed a 6.75% probability of overexposure with 15 mg, 42.4% with 30 mg, and 84.25% with 60 mg.
CONCLUSION: Estimated PK parameters in geriatric patients differed from those reported in pivotal trial populations, suggesting increased exposure, thereby potentially influencing bleeding risk. The impact of PPIs was not clinically relevant. Further investigation is needed to assess the benefits of alternative dosing in this population.
OBJECTIVES: To characterize the dose-exposure relationship and predict the sufficiency of current fixed-dose guideline for geriatric patients.
METHODS: We conducted a single-center prospective PK study in geriatric inpatients. We built a population PK model and used it to simulate various dosing strategies (n = 1000 simulations).
RESULTS: Seventeen frail geriatric patients (median age, 87 years; IQR, 83-90) receiving routine edoxaban contributed a total of 85 steady-state PK samples. A 2-compartment population PK model best described the edoxaban and M4 metabolite concentrations, with proton pump inhibitors (PPIs) reducing relative bioavailability by 24%. Key parameters included an absorption rate constant of 0.104 per hour, clearance of 9.02 L/h, and central and peripheral volumes of 47.4 L and 42.7 L, respectively. Edoxaban concentrations correlated with factor Xa inhibitor concentrations (ρ = .966). Nearly half of the patients had minimum concentrations > 43 ng/mL, with no difference between PPI and non-PPI groups. Simulations showed a 6.75% probability of overexposure with 15 mg, 42.4% with 30 mg, and 84.25% with 60 mg.
CONCLUSION: Estimated PK parameters in geriatric patients differed from those reported in pivotal trial populations, suggesting increased exposure, thereby potentially influencing bleeding risk. The impact of PPIs was not clinically relevant. Further investigation is needed to assess the benefits of alternative dosing in this population.